Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Covington
Dow
Queensland Health
UBS
Cerilliant
Cantor Fitzgerald
Farmers Insurance
Mallinckrodt
Baxter

Generated: October 17, 2017

DrugPatentWatch Database Preview

EUCRISA Drug Profile

« Back to Dashboard

What is the patent landscape for Eucrisa, and when can generic versions of Eucrisa launch?

Eucrisa is a drug marketed by Anacor Pharms Inc and is included in one NDA. There are four patents protecting this drug.

This drug has one hundred and six patent family members in twenty-two countries.

The generic ingredient in EUCRISA is crisaborole. One supplier is listed for this compound. Additional details are available on the crisaborole profile page.

Summary for Tradename: EUCRISA

US Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Drug Prices:see details
DailyMed Link:EUCRISA at DailyMed

Pharmacology for Tradename: EUCRISA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Anacor Pharms Inc
EUCRISA
crisaborole
OINTMENT;TOPICAL207695-001Dec 14, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Anacor Pharms Inc
EUCRISA
crisaborole
OINTMENT;TOPICAL207695-001Dec 14, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Anacor Pharms Inc
EUCRISA
crisaborole
OINTMENT;TOPICAL207695-001Dec 14, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Anacor Pharms Inc
EUCRISA
crisaborole
OINTMENT;TOPICAL207695-001Dec 14, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Anacor Pharms Inc
EUCRISA
crisaborole
OINTMENT;TOPICAL207695-001Dec 14, 2016RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: EUCRISA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,722,917Boron-containing small molecules► Subscribe
7,582,621Boron-containing small molecules► Subscribe
9,549,938Boron-containing small molecules► Subscribe
9,566,289Boron-containing small molecules► Subscribe
8,115,026Boron-containing small molecules► Subscribe
9,029,353Boron-containing small molecules as anti-inflammatory agents► Subscribe
8,440,642Boron-containing small molecules► Subscribe
8,889,656Boron-containing small molecules► Subscribe
7,767,657Boron-containing small molecules► Subscribe
9,353,133Boron-containing small molecules► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: EUCRISA

Country Document Number Estimated Expiration
Hong Kong1121344► Subscribe
South Korea20080110984► Subscribe
BrazilPI0708051► Subscribe
Mexico335993► Subscribe
China102532180► Subscribe
Israel207156► Subscribe
China101420854► Subscribe
Russian Federation2008131324► Subscribe
World Intellectual Property Organization (WIPO)2007095638► Subscribe
Russian Federation2010133524► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Fuji
Colorcon
Cerilliant
Julphar
UBS
Deloitte
US Department of Justice
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot